^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCM998

    i
    Other names: MCM998 , MCM-998, BCMA CART, CART-BCMA
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3years
    Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-ChargeTM Platform for the Treatment of Multiple Myeloma (ASH 2021)
    In addition to its unique phenotype, PHE885 secretes up to 25 fold more target specific IL-2 and ~7 fold more IFN gamma in vitro , when comparing to the TM products either using the same lentiviral vector (TM_PHE885) or a clinically validated anti-BCMA vector (MCM998) . Based on these results, a Phase 1, open-label trial assessing PHE885 in patients with r/r MM (NCT04318327) was initiated. Initial data from the dose escalation portion of the Phase 1 study will be presented separately.
    IO biomarker
    |
    IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCR7 (Chemokine (C-C motif) receptor 7)
    |
    MCM998 • durcabtagene autoleucel (PHE885)